Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Highlights of Recent Progress on March 3, 2022
Rain Therapeutics Inc. (NasdaqGS: RAIN) will report its financial results for Q4 and the full year ended December 31, 2021, on March 3, 2022. The late-stage precision oncology firm focuses on developing therapies targeting oncogenic drivers. A conference call will be held on the same day at 1:30 pm PT (4:30 pm ET) to discuss business and financial results. Rain’s lead product, milademetan, is an oral MDM2 inhibitor, and the company is also working on a preclinical program targeting RAD52.
- Upcoming financial results may highlight potential growth opportunities.
- Presentation of milademetan and its role in cancer treatment could attract investor interest.
- No current revenue data is available, which may concern investors.
- The lack of detailed financial metrics could hinder investment decisions.
NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and highlights of recent progress on Thursday, March 3, 2022. On that day, management will host a conference call and webcast at 1:30 pm PT (4:30 pm ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: March 3, 2022
Time: 1:30-2:30 pm PT (4:30-5:30 pm ET)
Dial In Numbers: 1 (833) 562-0127 (U.S. Toll Free) / 1 (661) 567-1105 (International)
Conference ID: 4729972
Webcast Link: https://edge.media-server.com/mmc/p/c4ut4zai
Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com
FAQ
When will Rain Therapeutics report its financial results for 2021?
What time is the conference call for Rain Therapeutics' financial results?
What is the lead product candidate of Rain Therapeutics?
How can I access the webcast for Rain Therapeutics' financial results?
